<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05077540</url>
  </required_header>
  <id_info>
    <org_study_id>aswu/543/8/21</org_study_id>
    <nct_id>NCT05077540</nct_id>
  </id_info>
  <brief_title>Oxytocin Versus, Sublingual Misoprostol in the Secondary Prevention of Postpartum Hemorrhage After Vaginal Delivery</brief_title>
  <official_title>The Effect of Oxytocin Versus, Sublingual Misoprostol in the Secondary Prevention of Postpartum Hemorrhage After Vaginal Delivery: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aswan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aswan University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Researchers sought to see how oxytocin versus, sublingual misoprostol affected estimated and&#xD;
      measured blood loss during vaginal delivery in women who had blood loss &gt;300 ml .&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The greatest cause of maternal mortality globally is postpartum hemorrhage (PPH), which is&#xD;
      defined as a blood loss of 500 mL or more after birth. All women giving birth should be given&#xD;
      a preventive uterotonic drug, according to the World Health Organization (WHO).&#xD;
&#xD;
      Despite the use of a uterotonic drug as a preventative measure, PPH remains a frequent&#xD;
      complication, accounting for one-quarter of all maternal fatalities worldwide. When&#xD;
      prophylaxis fails and PPH develops, it is advised that uterotonic medicines be used as&#xD;
      first-line therapy. However, it's unclear whether the uterotonic drug is better for treating&#xD;
      PPH as first-line therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>double-blinded a randomized controlled trial</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>double-blinded a randomized controlled trial</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>measured excessive bleeding blood loss ≥ 300 mills after PPH treatment</measure>
    <time_frame>24 hours</time_frame>
    <description>measured amount of blood loss ≥ 300 mills after PPH treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in hemoglobin</measure>
    <time_frame>12 hours</time_frame>
    <description>measure change of hemoglobin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>need for additional interventions</measure>
    <time_frame>24 hours</time_frame>
    <description>number of patients need additional interventions ,like uterine aetry ligation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Labor Complication</condition>
  <arm_group>
    <arm_group_label>oxytocin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>20 unit of oxytocin infusion in 500 ml lactated ringer's solution 125 ml/h (Syntocinon, Novartis, Switzerland)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>misoprostol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>800 µg sublingual misoprostol (Cytotec Pfizer, New York, USA)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxytocin</intervention_name>
    <description>20 unit of oxytocin infusion in 500 ml lactated ringer's solution 125 ml/h (Syntocinon, Novartis, Switzerland)</description>
    <arm_group_label>oxytocin</arm_group_label>
    <other_name>Active Comparator</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>misoprostol</intervention_name>
    <description>800 µg sublingual misoprostol (Cytotec Pfizer, New York, USA)</description>
    <arm_group_label>misoprostol</arm_group_label>
    <other_name>Active Comparator</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  vaginal birth in women who had blood loss &gt;300 ml&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  &lt;37 weeks of pregnancy,&#xD;
&#xD;
          -  genital tract injuries,&#xD;
&#xD;
          -  coagulation deficit,&#xD;
&#xD;
          -  hypertension, preeclampsia,&#xD;
&#xD;
          -  cardiac, renal, or hepatic disease,&#xD;
&#xD;
          -  epilepsy,&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>vaginal birth in women who had blood loss &gt;300 ml</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>hany f sallam, md</last_name>
    <phone>+201112501460</phone>
    <phone_ext>002</phone_ext>
    <email>hany.farouk@aswu.edu.eg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>nahla w waer, md</last_name>
    <phone>+201022336052</phone>
    <phone_ext>002</phone_ext>
    <email>nahlagyn@yahoo.com</email>
  </overall_contact_backup>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 1, 2021</study_first_submitted>
  <study_first_submitted_qc>October 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2021</study_first_posted>
  <last_update_submitted>October 14, 2021</last_update_submitted>
  <last_update_submitted_qc>October 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aswan University Hospital</investigator_affiliation>
    <investigator_full_name>hany farouk</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Postpartum Hemorrhage</mesh_term>
    <mesh_term>Obstetric Labor Complications</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Misoprostol</mesh_term>
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

